Bidding Dates
06 Jan 25 - 08 Jan 25
Price Range ₹
133 - 140
Total Equity
₹ 291.61Cr
Lot Size
107
Exchange Status
NSE,BSE
IPO Doc
Non-Institutional Investor
64.99×
Qualified Institutional Buyers
331.60×
Employees
0.00×
Retail Investors
64.99×
Total subscription Rate
183.18×
Offer start
06 Jan 2025
Offer end
08 Jan 2025
Allotment
09 Jan 2025
Refund initiation
10 Jan 2025
Demat transfer
10 Jan 2025
Listing
13 Jan 2025
Offer start
06 Jan 2025
Offer end
08 Jan 2025
Allotment
09 Jan 2025
Refund initiation
10 Jan 2025
Demat transfer
10 Jan 2025
Listing
13 Jan 2025
Standard Glass Lining Technology Limited, established in September 2012, is a leading manufacturer of engineering equipment for the pharmaceutical and chemical industries in India. The company has the capability to handle the complete production process internally, offering turnkey solutions that encompass design, engineering, manufacturing, assembly, installation, and the creation of standard operating procedures for its clients in these sectors. Its diverse product portfolio includes Reaction Systems, Storage, Separation and Drying Systems, and Plant Engineering and Services. The company specializes in manufacturing high-quality engineering equipment using materials such as glass-lined steel, stainless steel, and nickel alloy. Notable customers include prominent names like Apitoria Pharma, Aurobindo Pharma, CCL Food and Beverages, Cohance Lifesciences, Cadila Pharmaceuticals, Deccan Fine Chemicals, Laurus Labs, Granules India, Macleods Pharmaceuticals, MSN Laboratories, Natco Pharma, and several others from the pharmaceutical and chemical industries. The company operates eight manufacturing facilities located in Hyderabad, Telangana, and has sales offices in Vadodara, Ankleshwar, Mumbai, and Vishakhapatnam. With a pan-India sales network covering regions like Jhagadia, Chennai, New Delhi, Bengaluru, and Vijayawada, it ensures wide-reaching distribution. As of September 30, 2024, Standard Glass Lining Technology employs 460 full-time staff and 731 contract workers. Its competitive advantages include its specialization in engineering equipment for the pharmaceutical and chemical sectors, an innovative product range tailored to the needs of the industry, strategically located manufacturing units equipped with advanced technology, strong relationships with a prestigious client base, and a proven record of steady, profitable growth.
Year Founded
06-09-2012
Promotor Details
Sambasiva Rao Gollapudi
Particular | Pre-IPO | Post-IPO |
---|---|---|
Percentage | 75.69 | 60.41 |
Share Capital | 137486350 | 120506350 |
2,08,29,567.00 Cr
Years | Total Assets | Share Capital | Profit After Tax | Consolidated Net Profit | Adjusted EPS |
---|---|---|---|---|---|
2022 | 3,052.56 | 153.00 | 251.45 | 251.45 | 1.6435 |
2024 | 6,845.28 | 181.63 | 600.11 | 583.84 | 3.2144 |
2023 | 3,624.98 | 157.85 | 534.24 | 534.24 | 3.3845 |